Precision BioSciences
Precision BioSciences, headquartered in Durham, NC, specializes in developing in vivo gene editing therapies for genetic and infectious diseases using its ARCUS genome editing platform.
Services
Precision BioSciences specializes in developing in vivo gene editing therapies aimed at treating genetic and infectious diseases. The company focuses on sophisticated gene edits utilizing its proprietary ARCUS genome editing platform. The platform allows for precise and versatile gene editing capabilities, which include gene insertion, excision, and elimination.
Products
Precision BioSciences has a robust pipeline of gene editing therapies. Notable products include PBGENE-HBV, designed for the treatment of chronic hepatitis B, and PBGENE-PMM, aimed at treating primary mitochondrial myopathy. The company's technology is the basis for collaborations with other entities to expand their therapeutic success.
Partnerships
Precision BioSciences has established significant partnerships to advance its gene editing programs. The company is partnered with Novartis to develop a gene editing program targeting sickle cell disease and beta thalassemia. Additionally, Precision BioSciences collaborates with Prevail Therapeutics focusing on gene editing for Duchenne muscular dystrophy and other targets.
History
Founded in 2006 by postdoctoral fellows from Duke University, Precision BioSciences is located at 302 East Pettigrew St., Durham, NC 27701. The company has grown to make significant strides in the field of gene editing, ultimately going public and trading on NASDAQ under the ticker symbol DTIL.
Technology
Precision BioSciences utilizes the ARCUS genome editing platform, known for its precision and versatility. The platform allows for targeted gene edits, making it crucial for various therapeutic applications. The technology's capabilities include gene insertion, excision, and elimination, positioning the company at the forefront of gene editing science.
